TissueGen
TissueGen is a private Dallas-area drug delivery technology company licensing a proprietary two-phase emulsion platform that encapsulates sensitive biologics into biodegradable fibers, coils, microparticles, and nanoparticles for pharmaceutical and biotechnology partners.
- Company typePrivate
- Founded2000
- HeadquartersDallas, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What TissueGen does
TissueGen, Inc. is a privately held drug delivery technology company headquartered in Irving, Texas (Dallas metro), founded in 2000 as a spin-out of the Joint Program of Biomedical Engineering at the University of Texas Southwestern Medical Center and the University of Texas at Arlington. The company develops a proprietary two-phase emulsion encapsulation platform enhanced with nanotechnology that enables sensitive biological therapeutics — including antibodies, cytokines, and growth factors — to be loaded into biodegradable polymer delivery systems while preserving greater than 90% of their biological activity post-processing. The core technical problem solved is the historical incompatibility between harsh fiber extrusion conditions and fragile biologics, originally addressed by founder Kevin D. Nelson, PhD.
The product portfolio spans four delivery formats built on the same platform architecture: wet-extruded drug-eluting biodegradable fibers (the original format, capable of release over days to months and formable into woven, knitted, braided, or independent suture constructs); drug-eluting shape-set coils that create three-dimensional drug concentration gradients; a microparticle platform for injectable delivery of water-soluble drugs via small-gauge needles; and a nanoparticle process for protecting and distributing therapeutics into polymer solutions. IP coverage includes 30 patents and applications across 19 jurisdictions, with granted claims on drug-eluting self-retaining sutures, biomolecule conformation preservation, self-expanding medical devices, and the core drug-releasing biodegradable fiber process.
TissueGen operates a B2B enterprise technology licensing and partnership model, targeting pharmaceutical and biotechnology companies that need advanced delivery formats for complex or temperature-sensitive therapeutics. The company is not a product retailer; it monetizes its platform through licensing and co-development arrangements with drug developers. The team consists of approximately 15 personnel across executive management, a four-person board of directors (including the founder), a three-person advisory board, and technical staff. A notable capital event was a $42 million patent infringement verdict awarded jointly to TissueGen and the University of Texas System against Boston Scientific, evidencing enforceable IP value but not recurring revenue.
TissueGen firmographics
Firmographics- Name
- TissueGen
- Legal name
- TissueGen, Inc.
- Website
- https://tissuegen.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- TissueGen is a private Dallas-area drug delivery technology company licensing a proprietary two-phase emulsion platform that encapsulates sensitive biologics into biodegradable fibers, coils, microparticles, and nanoparticles for pharmaceutical and biotechnology partners.
- Ownership category
- akta.pro rank
TissueGen industry classification
Industry- Product category
- Pharmaceutical Drug Delivery Technology
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Plastics Material and Resin Manufacturing (325211)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Miscellaneous Plastics Products (3080)
- akta.pro primary industry
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
Keywords
Where TissueGen is headquartered
LocationHeadquarters
- HQ city
- Dallas
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TissueGen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Technology Licensing: Licensing proprietary drug delivery technology and encapsulation platform to pharmaceutical and biotech companies for development of extended-release therapeutics.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
TissueGen product offering
Product offeringCore offering
TissueGen develops a proprietary two-phase drug delivery platform that uses biodegradable polymers and nanotechnology to encapsulate sensitive biological therapeutics — including antibodies, growth factors, cytokines, and plasmid DNA — into extended-release formats. The company manufactures and licenses drug-eluting fibers, drug-eluting coils, microparticles, and nanoparticles designed to deliver biologics without degradation across nerve, vascular, and ophthalmic applications.
Product overview
TissueGen is a drug delivery technology company that developed a proprietary encapsulation platform enabling the delivery of complex therapeutics, from small molecules to temperature and chemically sensitive biologics such as antibodies, cytokines, and growth factors. The platform comprises four distinct delivery formats: Drug-Eluting Fibers (biodegradable extruded fibers for extended release over days to months), Drug-Eluting Coils (shape-set fibers providing 3D drug concentration gradients), Microparticles (injectable particles for water-soluble drugs), and Nanoparticles (for protecting and distributing therapeutic agents into polymer solutions). The company uses approved biodegradable polymers and a two-phase emulsion system incorporating nanotechnology to preserve biological activity during processing.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug-Eluting Fibers
- Drug-Eluting Coils
- Microparticle Platform
- Nanoparticle Platform
- Proprietary Encapsulation Technology Licensing
Quantifiable outcome
- Greater than 90% preserved biological activity post-fiber extrusion for several antibodies and growth factors
- +1 more outcomes
Companies that use TissueGen
Customer profileSegments2 records
Ideal customer profiles2 records
TissueGen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
TissueGen partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- University of Texas Southwestern Medical Center at DallascoreTissueGen was founded in 2000 as a spin-out of the Joint Program of Biomedical Engineering at UT Southwestern Medical Center at Dallas and UT Arlington. Initial technology was developed by founder Dr. Kevin Nelson at these institutions.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
TissueGen competitors and assessment
Company assessmentBroad incumbents
- Pacira BioSciences: Pacira commercializes proprietary extended-release injectable drug delivery technologies and serves as a benchmark for how a polymer-based delivery platform can scale into a commercial pharma business — a relevant aspirational peer for TissueGen.
- Ashland: Ashland's Life Sciences division provides pharmaceutical excipients, controlled-release polymers, and drug-delivery formulation support, competing with TissueGen for pharma licensing and co-development engagements.
- DSM Biomedical (dsm-firmenich): DSM Biomedical supplies biomedical-grade polymers and drug-eluting device materials to the medical and pharmaceutical industries, overlapping with TissueGen's biodegradable delivery formats and licensing-style customer model.
- Lubrizol Life Science: Lubrizol Life Science produces engineered polymers and excipients for pharmaceutical drug delivery, including controlled-release systems — a broad incumbent serving the same pharma licensing customer base as TissueGen.
- Evonik Industries: Evonik's Health Care division supplies RESOMER biodegradable polymers and formulation services for parenteral drug delivery, including sustained-release microparticles and implants — directly overlapping with TissueGen's polymer-based extended-release platform.
- Corbion: Corbion produces bioresorbable polymers (PURASORB) used in drug delivery and medical devices, and supplies biomaterial inputs comparable to TissueGen's approved-polymer foundation for extended-release therapeutics.
Direct peers
- PolyPid: PolyPid develops polymer-based drug delivery platforms for localized, prolonged therapeutic release — directly comparable in product architecture and B2B pharma partnership strategy.
- Innocore Pharmaceuticals: Innocore specializes in biodegradable polymeric drug delivery systems including injectable sustained-release formulations — a closely aligned business model and technology stack to TissueGen's microparticle and fiber platform.
- Surmodics: Surmodics develops drug-delivery coatings and polymer-based combination products for medical devices and pharmaceuticals, making it a direct peer in polymer-encapsulated, sustained-release therapeutic delivery.
Emerging players
- Bezwada Biomedical: Bezwada Biomedical develops absorbable polymers and bioabsorbable medical products, including drug-eluting formats, with a smaller-scale, innovation-driven profile comparable to TissueGen's specialist platform approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
TissueGen social profiles
Digital presenceTissueGen financial estimates
Financial estimateRevenue estimate
Valuation estimate
TissueGen leadership team
Management profileNumber of profiles
Profiles5 records
TissueGen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TissueGen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TissueGen
What does TissueGen do?
TissueGen develops a proprietary two-phase drug delivery platform that uses biodegradable polymers and nanotechnology to encapsulate sensitive biological therapeutics — including antibodies, growth factors, cytokines, and plasmid DNA — into extended-release formats. The company manufactures and licenses drug-eluting fibers, drug-eluting coils, microparticles, and nanoparticles designed to deliver biologics without degradation across nerve, vascular, and ophthalmic applications.
Is TissueGen a public or private company?
TissueGen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was TissueGen founded?
TissueGen was founded in 2000. It employs 1 to 10 people.
Where is TissueGen based?
TissueGen is headquartered in Dallas, United States, in the North America region.
How does TissueGen make money?
One revenue line is on record: technology Licensing.
Who are TissueGen's main competitors?
Broad incumbents on record are Pacira BioSciences, Ashland, DSM Biomedical (dsm-firmenich), Lubrizol Life Science, Evonik Industries and Corbion. Direct peers are PolyPid, Innocore Pharmaceuticals and Surmodics. Bezwada Biomedical is listed as an emerging player.
Does TissueGen have an API?
No public API is recorded for TissueGen.
What industry is TissueGen in?
TissueGen's product category is Pharmaceutical Drug Delivery Technology. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 3391 and its SIC code is 3842.